中国医药科学2023,Vol.13Issue(24):87-91,5.DOI:10.20116/j.issn2095-0616.2023.24.21
子痫前期患者外周血中性粒细胞TLR9表达及其临床意义
The expression of TLR9 in peripheral blood neutrophils of patients with preeclampsia and its clinical significance
摘要
Abstract
Objective To explore the expression level of Toll-like receptor 9(TLR9)in peripheral blood neutrophils of patients with preeclampsia(PE)and its role in the pathogenesis of preeclampsia.Methods 34 patients with preeclampsia(the PE group)and 34 healthy pregnant women(the NP group)who were hospitalized in the Department of Obstetrics and Gynecology of Wuxi People's Hospital from March 2021 to December 2022 were selected,their peripheral blood was collected,and flow cytometer was used to test the expression level of neutrophil TLR9.Real-time fluorescence quantitative PCR was used to test the concentration of plasma mitochondrial DNA(mtDNA).Enzyme-linked immunosorbent assay(ELISA)was used to test the concentrations of calprotectin,myeloperoxidase,and interleukin(IL)-8.Peripheral blood neutrophils were separated and co-cultured with the TLR9 ligand CpG-ODN 2006.The ELISA was used to test concentrations of supernatant calprotectin,myeloperoxidase,and IL-8.Results The expression level of TLR9 in neutrophils and plasma mitochondrial DNA(mtDNA)concentration in the PE group were significantly higher than those in the NP group,with statistically significant differences(P<0.05).The concentrations of calprotectin,myeloperoxidase,and IL-8 in the peripheral plasma and co-culture supernatant of patients in the PE group were significantly higher than those in the NP group,with statistically significant differences(P<0.05).Conclusion The abnormal activation of the TLR9 signaling pathway in peripheral blood neutrophils of patients with preeclampsia is involved in the process of preeclampsia.关键词
子痫前期/中性粒细胞/Toll样受体9/线粒体DNAKey words
Preeclampsia/Neutrophils/Toll-like receptor 9/Mitochondrial DNA分类
医药卫生引用本文复制引用
邹应芬,李鹰,赵翠翠,龚玲丽,马锦琪..子痫前期患者外周血中性粒细胞TLR9表达及其临床意义[J].中国医药科学,2023,13(24):87-91,5.基金项目
江苏省无锡市卫生健康委妇幼健康科研项目(FYKY202102). (FYKY202102)